share_log

The Total Return for Mingchen HealthLtd (SZSE:002919) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years

The Total Return for Mingchen HealthLtd (SZSE:002919) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years

在過去五年中,明晨健康有限公司(深圳證券交易所:002919)投資者的總回報增長速度快於收益增長
Simply Wall St ·  05/25 22:42

Mingchen Health Co.,Ltd. (SZSE:002919) shareholders might be concerned after seeing the share price drop 25% in the last quarter. On the bright side the returns have been quite good over the last half decade. It has returned a market beating 81% in that time. While the long term returns are impressive, we do have some sympathy for those who bought more recently, given the 45% drop, in the last year.

名臣健康股份有限公司(SZSE:002919)的股東們在過去的一季度中看到股價下跌了25%後,可能會感到擔憂。 光明的是,在過去的五年中,其回報一直相當不錯。在這段時間裏,它的回報率高達81%,超過了市場。 雖然長期回報令人印象深刻,但是我們確實對那些近期買入的人表示同情,因爲在過去一年中股價已經下跌了45%。

In light of the stock dropping 10% in the past week, we want to investigate the longer term story, and see if fundamentals have been the driver of the company's positive five-year return.

鑑於股票已在過去一週內下跌了10%,我們想調查更長期的故事,看看基本面是否一直是公司五年回報的驅動因素。

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

在他的文章《格雷厄姆和多德斯維爾超級投資者》中,禾倫·巴菲特描述了股票價格並不總是反映公司價值的合理方式。考慮市場對公司的看法如何發生變化的一個不完美但簡單的方法是將每股收益(EPS)的變化與股價的變動進行比較。股票價格並不總是反映公司價值的合理方式禾倫·巴菲特曾稱,股票價格並不總是合理地反映了企業的價值。檢查市場情緒如何隨時間變化的一種方法是查看公司股價和每股收益(EPS)之間的互動。

Over half a decade, Mingchen HealthLtd managed to grow its earnings per share at 23% a year. This EPS growth is higher than the 13% average annual increase in the share price. So it seems the market isn't so enthusiastic about the stock these days.

在半個十年的時間裏,名臣健康股份有限公司的每股收益增長率達到了23%。 這種每股收益增長高於股價平均每年增長的13%。 因此,目前市場對該股票的熱情不是太高。

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

下面可以看到每股收益隨時間的變化情況(通過點擊圖像來查看確切數值)。

earnings-per-share-growth
SZSE:002919 Earnings Per Share Growth May 26th 2024
SZSE:002919每股收益增長2024年5月26日

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.

在購買或出售股票之前,我們始終建議仔細研究歷史增長趨勢,此處提供。

What About The Total Shareholder Return (TSR)?

那麼,股東總回報(TSR)呢?

We've already covered Mingchen HealthLtd's share price action, but we should also mention its total shareholder return (TSR). The TSR attempts to capture the value of dividends (as if they were reinvested) as well as any spin-offs or discounted capital raisings offered to shareholders. Mingchen HealthLtd's TSR of 86% for the 5 years exceeded its share price return, because it has paid dividends.

我們已經涵蓋了名臣健康股份有限公司的股價情況,但我們還應該提到它的總股東回報率(TSR)。 TSR試圖捕捉股息的價值(就像它們被再投資一樣),以及提供給股東的任何分拆或折價融資。 名臣健康股份有限公司的5年TSR超過了股價回報,因爲它已經支付了股息。

A Different Perspective

不同的觀點

While the broader market lost about 10% in the twelve months, Mingchen HealthLtd shareholders did even worse, losing 45%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 13% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. Before forming an opinion on Mingchen HealthLtd you might want to consider these 3 valuation metrics.

儘管整個市場在過去的12個月中損失了約10%,但名臣健康股份有限公司的股東們表現得更糟,損失了45%。 但是,這可能僅是股價受到更廣泛的市場恐慌的影響。 如果基本面繼續表明有長期可持續增長的機會,目前的拋售可能是值得考慮的機會。 光明的是,長期股東已經賺到了錢,長達五年的年回報率達到13%。 在對名臣健康股份有限公司形成意見之前,您可能需要考慮這三個估值指標。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).

如果您喜歡與管理層一起購買股票,那麼您可能會喜歡這個公司的免費列表。 (提示:其中許多公司不爲人注意且具有吸引力的估值。)

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論